吉米沙星与左氧氟沙星治疗下呼吸道感染的随机对照比较

Gemifloxacin versus levofloxacin in treatment of lower respiratory tract infection:a randomized controlled trial

目的:评价吉米沙星治疗下呼吸道感染的有效性和安全性。方法:采用随机对照单盲试验。33例下呼吸道感染病人,其中社区获得性肺炎(CAP)14例,慢性支气管炎急性发作(AECB)19例,随机分为2组,试验组17例,对照组16例。试验组予吉米沙星320 mg,每日1次,CAP病人疗程7～14 d,AECB病人疗程5 d。对照组予左氧氟沙星200 mg,每日2次,CAP病人疗程7～14 d,AECB病人疗程7 d。结果:治疗结束后d 1,临床有效率试验组为71%,对照组为93%;治疗结束后d 7,临床有效率2组均为100%。2组疗效比较无显著差异(P>0.05),不良反应发生率亦无显著差异(P>0.05)。结论:吉米沙星与左旋氧氟沙星治疗下呼吸道感染的临床疗效相似。

AIM： To evaluate the safety and efficacy of gemifloxacin in the treatment of lower respiratory infection. METHODS： A randomized controlled single-blind clinical trial of gemifloxacin vs levofloxacin was conducted among 33 patients with lower respiratory infection. The patients were divided into two groups randomly with 17 in the trial group and 16 in the control group. There were 14 community-acquired pneumonia （CAP） patients with 7 in each group and 19 acute exacerbations of chronic bronchitis （AECB） patients with 10 in the trial group and 9 in control one. The patients in the trial group were treated with gemifloxacin, 320 mg, po, qd, for a course of 7-14 d in CAP patients and a course of 5 d for the AECB ones. Other patients in the control group were treated with levofloxacin, 200 mg, po, bid, with a course of 7-14 d for the CAP patients and a course of 7 d for those of AECB. RESULTS： At 1 d post treatment, the efficacy rates were 71% and 93 % for the trial group and control group, while both were 100 % at 7 d post treatment. There was no significant difference between two groups in clinical efficacy （P 〉 0.05） and adverse reactions （P 〉 0.05） . CONCLUSION： Gemifloxacin is as effective and safe as levofloxacin in the treatment of lower respiratory infection.